CRIS Current Research Information System

PINNA, ANTONIO DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.786
AS - Asia 26.734
EU - Europa 20.300
AF - Africa 1.800
SA - Sud America 1.657
Continente sconosciuto - Info sul continente non disponibili 1.334
OC - Oceania 36
Totale 87.647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 35.334
VN - Vietnam 8.034
SG - Singapore 7.157
CN - Cina 6.182
GB - Regno Unito 5.611
DE - Germania 2.755
IT - Italia 2.561
SE - Svezia 2.277
HK - Hong Kong 1.664
IN - India 1.511
FR - Francia 1.473
RU - Federazione Russa 1.220
BR - Brasile 1.191
UA - Ucraina 1.180
IE - Irlanda 837
ZA - Sudafrica 567
NL - Olanda 455
JP - Giappone 454
EE - Estonia 427
FI - Finlandia 355
CI - Costa d'Avorio 345
TG - Togo 341
BD - Bangladesh 337
CH - Svizzera 303
SC - Seychelles 243
KR - Corea 238
CA - Canada 227
BG - Bulgaria 214
AR - Argentina 201
JO - Giordania 175
NG - Nigeria 150
PH - Filippine 135
TH - Thailandia 123
BE - Belgio 115
IQ - Iraq 99
MX - Messico 95
EC - Ecuador 86
AT - Austria 85
PL - Polonia 84
ES - Italia 82
ID - Indonesia 80
TR - Turchia 75
PK - Pakistan 71
IR - Iran 61
GR - Grecia 60
SA - Arabia Saudita 57
TW - Taiwan 55
CL - Cile 48
CO - Colombia 45
UZ - Uzbekistan 37
RO - Romania 36
MY - Malesia 33
LB - Libano 29
MA - Marocco 29
AU - Australia 28
HR - Croazia 27
JM - Giamaica 26
LT - Lituania 25
PE - Perù 25
CR - Costa Rica 24
VE - Venezuela 22
PY - Paraguay 21
EG - Egitto 20
ET - Etiopia 20
DZ - Algeria 16
KE - Kenya 15
NP - Nepal 15
AE - Emirati Arabi Uniti 14
AL - Albania 13
DK - Danimarca 13
NO - Norvegia 13
UY - Uruguay 13
AZ - Azerbaigian 12
CZ - Repubblica Ceca 12
DO - Repubblica Dominicana 12
HN - Honduras 12
TN - Tunisia 12
OM - Oman 10
IL - Israele 9
MD - Moldavia 9
NI - Nicaragua 9
PS - Palestinian Territory 9
PT - Portogallo 9
KZ - Kazakistan 8
EU - Europa 7
KH - Cambogia 7
LY - Libia 7
SI - Slovenia 7
SK - Slovacchia (Repubblica Slovacca) 7
SV - El Salvador 7
BS - Bahamas 6
SN - Senegal 6
TT - Trinidad e Tobago 6
LK - Sri Lanka 5
LV - Lettonia 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AO - Angola 4
Totale 86.205
Salva come PNG Salva come JPEG
Città #
Southend 5.014
Singapore 4.878
Fairfield 3.994
Ashburn 3.394
Chandler 2.306
Woodbridge 1.990
Dong Ket 1.785
Houston 1.748
Wilmington 1.728
Seattle 1.607
Hong Kong 1.576
Ho Chi Minh City 1.568
San Jose 1.554
Cambridge 1.429
Santa Clara 1.333
Hanoi 1.280
Princeton 1.204
Ann Arbor 1.053
Dublin 786
Beijing 767
Boardman 693
Council Bluffs 673
Jacksonville 664
Nanjing 561
Lauterbourg 559
Westminster 530
Padova 481
Hefei 453
Bologna 450
Los Angeles 429
Tokyo 404
Berlin 367
New York 360
Abidjan 345
Lomé 341
Dallas 339
Helsinki 307
Jinan 272
Saint Petersburg 268
Bern 256
Shenyang 254
Buffalo 253
San Diego 234
Haiphong 223
Munich 220
Da Nang 217
Sofia 212
Changsha 179
São Paulo 177
Milan 175
Amman 170
Nanchang 167
Hebei 165
Dearborn 164
Seoul 164
Redondo Beach 159
Frankfurt am Main 156
Turin 155
Florence 149
Guangzhou 139
Mülheim 139
Medford 135
Shanghai 128
Tianjin 125
Abeokuta 118
Jiaxing 114
Menlo Park 112
Brussels 110
Delhi 106
Zhengzhou 103
Bremen 100
The Dalles 96
Phoenix 95
Hangzhou 94
Falls Church 93
Norwalk 93
Redmond 87
Johannesburg 83
Hải Dương 82
Redwood City 81
Olalla 78
Des Moines 77
Toronto 77
Chicago 75
Biên Hòa 74
Rome 73
Ningbo 69
Can Tho 67
London 65
Mahé 63
Orem 63
Haikou 60
Lanzhou 60
Falkenstein 59
Montreal 58
Yubileyny 56
Fuzhou 55
Atlanta 54
Thái Nguyên 52
Vienna 52
Totale 56.859
Salva come PNG Salva come JPEG
Nome #
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 522
Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors 505
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 403
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 343
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 333
A comprehensive analysis on expected years of life lost due to pancreatic cancer 313
Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome 303
Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy 297
Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors:First Italian Clinical Trial 285
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 284
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 280
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 275
Prognostic criteria for postoperative mortality in 170 patients undergoing major right hepatectomy 272
A new liver transplant priority for patients with hepatocellular carcinoma. 269
Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. 263
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 259
Burnout and psychological distress between surgical and non-surgical residents 259
Antifungal prophylaxis in liver transplant recipients: one size does not fit all 258
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 257
Infections in liver and lung transplant recipients: A national prospective cohort 256
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 255
Comprehensive surgical intestinal rescue and transplantation program in adult patients: Bologna experience. 251
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 248
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 246
Anticorpi anti-HLA preformati e Trapianto Combinato Rene-Fegato. Caso clinico. 245
Surgical therapy for hepatolithiasis: a Western experience. 242
Multimodal Surgical Approach for Adult Patients With Chronic Intestinal Pseudo-Obstruction: Clinical and Psychosocial Long-term Outcomes 242
Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. 241
Combined liver-kidney transplantation: the experience of the University of Bologna and the case of preoperative positive cross-match. 241
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 241
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 240
Conventional split liver transplantation for two adult recipients: a recent experience in a single European center 235
Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts. 234
A partnership model between high- And low-volume hospitals to improve results in hepatobiliary pancreatic surgery 232
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective 232
A new prognostic model to predict drop-out from the waiting list in cirrhotic candidates for liver transplantation wirh MELD score <18. 230
A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts 230
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 229
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. 227
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 225
A Multicentric Study on Double Kidney Transplantation 225
Abdominal wall transplantation with microsurgical technique 225
Bacterial translocation in adult small bowel transplantation 224
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 223
Long-term endoscopic follow-up in small bowel transplant recipients: single-center series. 223
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 223
Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy 222
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
Combined kidney-liver, heart-liver, and kidney-pancreas transplantations from a single deceased donor. 221
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 219
Acute cellular rejection monitoring after interstinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. 218
Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation:a management challenge 218
A new liver extracorporeal device (LEONARDO) to treat swine with post-resection acute liver failure 217
Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. 217
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 217
COMBINED KIDNEY LIVER TRANSPLANTATION: A SINGLE CENTER EXPERIENCE 216
Combined liver–dual kidney transplant: Role in expanded donors 216
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 216
Liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical long-term follow-up and pathogenic implications 216
Associated benign liver tumors in idiopathic granulomatous hepatitis: a case report 215
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 215
ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. 215
Blood monitoring of granzyme B and perforin expression after intestinal transplantation: considerations on clinical relevance. 214
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? 214
Coping strategies in intestinal transplantation 214
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 214
Combined heart and liver transplantation for familial amyloidotic polyneuropathy. 213
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 213
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 212
Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: Towards tailoring of therapeutic strategies? 212
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 211
Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. 210
Trapianto Combinato Rene-Fegato: Esperienza del Policlinico S.Orsola di Bologna 210
Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. 210
Application of a fluorescent PCR method for molecular diagnosis of posttransplant lymphoproliferative disorders on routine tissue sections. 210
Abdominal wall defect repair with biological prosthesis in transplanted patients: single center retrospective analysis and review of the literature 209
Pre-transplant psoas muscle density as a ready-to-use and low-cost predictor of patient survival after liver transplant 208
Anatomic variations of intrahepatic bile ducts in a European series and meta-analysis of the literature. 208
Italian experience in adult clinical intestinal and multivisceral transplantation: 6 years later. 208
Increase of portal blood oxygenation by artero-venous shunt in diabetic rats 208
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 207
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. 207
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 206
Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. 206
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study 205
Prediction of Three-Year Outcome of Renal Transplantation from Optimal Donors versus Expanded Criteria Donors. 204
Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. 204
Thorough assessment of portal venous thrombosis in patients with HCC allows adequate selection of candidates for liver transplantation 204
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 203
Survival after the diagnosis of de novo malignancy in liver transplant recipients 203
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. 202
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. 201
Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma. 201
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 201
Combined heart-liver transplantation: A single-center experience 200
Psychological Adaptation and Quality of Life of Adult Intestinal Transplant Recipients: University of Bologna Experience 200
Transcatheter Embolization for Giant Splenic Artery Aneurisms: Still an Open Question 199
Combined liver-kidney transplantation-s. Orsola experience: nephrological aspects. 199
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 198
Totale 23.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 239.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 239.654
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228.994 0 403 591 794 955 535 236 630 356 507 2.252 1.735
2022/202310.182 1.139 1.611 579 1.339 621 704 268 551 1.767 241 859 503
2023/20242.442 201 478 121 263 170 507 117 173 83 171 71 87
2024/202510.237 425 1.858 822 764 1.896 521 608 254 123 652 258 2.056
2025/202624.490 2.407 1.967 2.222 1.663 2.735 1.669 2.464 851 4.858 1.988 832 834
2026/20271.319 490 829 0 0 0 0 0 0 0 0 0 0
Totale 87.647